$CGEM insider trading
Over the last 12 months, Cullinan Therapeutics insiders reported 3 buys totaling $13.3M and 24 sales totaling $2.5M across SEC Form 4 filings. 44% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $13.3M 3 events
- Sold · 12m
- $2.5M 24 events
- Events · 12m
- 27 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 44% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 8,000 | $21.57 | $173K | -4.8% | plan |
| Aug 13, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 30,000 | $20.26 | $608K | -15.6% | plan |
| Jul 6, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 8,000 | $17.82 | $143K | -4.7% | plan |
| May 5, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 8,000 | $14.62 | $117K | -4.6% | plan · 2 tranches |
| Mar 5, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 8,000 | $15.68 | $125K | -4.5% | plan |
| Feb 25, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 1,780 | $14.14 | $25K | -1% | plan |
| Feb 24, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 5,353 | $14.31 | $77K | -2.9% | plan · 2 tranches |
| Feb 24, 2026 | AHMED NADIMPresident and CEO · O·D | ▼ Sale | 13,515 | $14.47 | $196K | -3.3% | — |
| Feb 24, 2026 | Jones Jeffrey AlanChief Medical Officer · O | ▼ Sale | 4,582 | $14.47 | $66K | -2.8% | — |
| Feb 24, 2026 | SUMER JACQUELYN LChief Legal Officer · O | ▼ Sale | 3,601 | $14.47 | $52K | -2.7% | — |
| Feb 20, 2026 | Fenton Mary KayChief Financial Officer · O | ▼ Sale | 4,398 | $13.62 | $60K | -3.4% | — |
| Feb 20, 2026 | Jones Jeffrey AlanChief Medical Officer · O | ▼ Sale | 4,982 | $13.62 | $68K | -2.9% | — |
| Feb 20, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 11,742 | $14.08 | $165K | -6.1% | plan · 2 tranches |
| Feb 20, 2026 | SUMER JACQUELYN LChief Legal Officer · O | ▼ Sale | 3,742 | $13.62 | $51K | -2.8% | — |
| Feb 20, 2026 | AHMED NADIMPresident and CEO · O·D | ▼ Sale | 16,381 | $13.62 | $223K | -3.9% | — |
| Feb 12, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 416 | $12.03 | $5K | -0.3% | — |
| Jan 22, 2026 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 4,000 | $12.3 | $49K | -3% | plan |
| Dec 23, 2025 | AHMED NADIMPresident and CEO · O·D | ▼ Sale | 9,922 | $10.01 | $99K | -2.3% | late |
| Dec 19, 2025 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 1,345 | $10.01 | $13K | -1% | plan |
| Dec 18, 2025 | SUMER JACQUELYN LChief Legal Officer · O | ▼ Sale | 3,480 | $9.67 | $34K | -2.5% | — |
| Dec 18, 2025 | Jones Jeffrey AlanChief Medical Officer · O | ▼ Sale | 4,632 | $9.67 | $45K | -2.7% | — |
| Dec 18, 2025 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 2,898 | $9.67 | $28K | -2.1% | — |
| Dec 15, 2025 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 3,143 | $12.23 | $38K | -2.2% | plan · 2 tranches |
| Nov 24, 2025 | Michaelson JenniferChief Scientific Officer · O | ▼ Sale | 4,000 | $12.3 | $49K | -2.8% | plan |
| Oct 28, 2025 | Lynx1 Capital Management LP10% | ▲ Buy | 165,667 | $8.4 | $1.4M | +1.9% | indirect |
| Oct 17, 2025 | Lynx1 Capital Management LP10% | ▲ Buy | 248,749 | $8.46 | $2.1M | +2.9% | 4 tranches · indirect |
| Oct 10, 2025 | Lynx1 Capital Management LP10% | ▲ Buy | 1,459,641 | $6.73 | $9.8M | +20.6% | 3 tranches · indirect |
Every $CGEM filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Cullinan Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CGEM feed.